Summary

The intranasal drug delivery devices market was valued at $1.7 billion in 2023, and is projected to reach $3.8 billion by 2033, growing at a CAGR of 8.7% from 2024 to 2033.
Intranasal drug delivery devices are medical devices designed to administer therapeutic agents through the nasal cavity. This route of administration provides a non-invasive and efficient means to deliver drugs directly into the systemic circulation or target the central nervous system, bypassing the gastrointestinal tract and first-pass metabolism in the liver. Intranasal devices commonly include nasal sprays, nebulizers, and powder dispensers, tailored to enhance drug absorption through the nasal mucosa.

The growth of the global intranasal drug delivery devices market is driven by alarming increase in prevalence of respiratory diseases, allergies, migraines as well as conditions requiring rapid drug action, such as epilepsy and opioid overdose. According to a study published by the Institute for Health Metrics and Evaluation—a public health research institute—chronic respiratory diseases were responsible for 4.0 million deaths with a prevalence of 454.6 million cases in 2019, ranking as the third leading cause of death. In addition, surge in demand for non-invasive drug delivery methods among patients is boosting the adoption of intranasal devices for both chronic and acute conditions. Moreover, intranasal drug delivery is effective in targeting the central nervous system, as it allows drugs to bypass the blood-brain barrier. This is fostering research into treatments for neurological disorders, such as Alzheimer’s and Parkinson’s disease. Furthermore, rise of home healthcare and self-medication trends is driving the demand for easy-to-use drug delivery systems, including intranasal devices, which significantly fosters the market growth. However, frequent use of intranasal devices may cause irritation, dryness, or other discomfort in the nasal mucosa, which limits their adoption, thereby hampering the market growth. In addition, not all drugs are suitable for intranasal delivery due to stability issues or low permeability through the nasal mucosa, which restricts the range of applications for these devices. On the contrary, innovations such as metered-dose nasal sprays and needle-free devices improve drug delivery precision and user-friendliness. Smart devices integrated with sensors for dose tracking are also emerging, enhancing patient adherence. Such developments are expected to offer remunerative opportunities for the expansion of the global market during the forecast.

The intranasal drug delivery devices industry is segmented into system, container, application, and region. By system, the market is segregated into metered dose, multi-dose systems, and unit-dose systems. On the basis of containers, it is bifurcated into non-pressurized containers and pressurized containers. Depending on application, it is divided into chronic obstructive pulmonary disease (COPD) , rhinitis, cystic fibrosis, nasal congestion, asthma, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings
By system, the multi-dose systems segment is expected to dominate the market from 2024 to 2033.
On the basis of container, the non-pressurized system containers segment is anticipated to exhibit the highest growth during the forecast period.
Depending on application, the asthma segment is projected to grow at a notable pace in the near future.
Region wise, North America held the largest market share in the intranasal drug delivery devices market in 2023, and is expected to dominate the market during the forecast period.

Competition Analysis
Competitive analysis and profiles of the major players in the global intranasal drug delivery devices market include AptarGroup, Inc., Teleflex Incorporated, Nemera, Becton, Dickinson and Company, OptiNose, Inc., GlaxoSmithKline Plc., AstraZeneca, Kurve Technology, Inc., Johnson & Johnson, and Merck & Co., Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.


Additional benefits you will get with this purchase are:
● Quarterly Update and* (only available with a corporate license, on listed price)
● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
● Free Upcoming Version on the Purchase of Five and Enterprise User License.
● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
● Free data Pack on the Five and Enterprise User License. (Excel version of the report)
● Free Updated report if the report is 6-12 months old or older.
● 24-hour priority response*
● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
● Additional company profiles with specific to client's interest
● Historic market data
● Import Export Analysis/Data
Key Market Segments
By System
● Metered Dose
● Multi-Dose Systems
● Unit-Dose Systems
By Container
● Non-Pressurized Containers
● Pressurized Containers
By Application
● Chronic Obstructive Pulmonary Disease
● Rhinitis
● Cystic Fibrosis
● Nasal Congestion
● Others
By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ France
○ Germany
○ Italy
○ Spain
○ UK
○ Rest of Europe
● Asia-Pacific
○ China
○ Japan
○ India
○ South Korea
○ Australia
○ Rest of Asia-Pacific
● LAMEA
○ Brazil
○ South Africa
○ Saudi Arabia
○ Rest of LAMEA
● Key Market Players
○ AptarGroup, Inc.
○ Teleflex Incorporated
○ nemera
○ Becton, Dickinson and Company
○ OptiNose, Inc.
○ GlaxoSmithKline plc.
○ AstraZeneca
○ Kurve Technology, Inc.
○ Johnson & Johnson
○ Merck & Co., Inc.

ページTOPに戻る

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: INTRANASAL DRUG DELIVERY DEVICES MARKET, BY SYSTEM
4.1. Market Overview
4.1.1 Market Size and Forecast, By System
4.2. Metered Dose
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Multi-Dose Systems
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Unit-Dose Systems
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
CHAPTER 5: INTRANASAL DRUG DELIVERY DEVICES MARKET, BY CONTAINER
5.1. Market Overview
5.1.1 Market Size and Forecast, By Container
5.2. Non-Pressurized Containers
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Pressurized Containers
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: INTRANASAL DRUG DELIVERY DEVICES MARKET, BY APPLICATION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Application
6.2. Chronic Obstructive Pulmonary Disease
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Rhinitis
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Cystic Fibrosis
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
6.5. Nasal Congestion
6.5.1. Key Market Trends, Growth Factors and Opportunities
6.5.2. Market Size and Forecast, By Region
6.5.3. Market Share Analysis, By Country
6.6. Others
6.6.1. Key Market Trends, Growth Factors and Opportunities
6.6.2. Market Size and Forecast, By Region
6.6.3. Market Share Analysis, By Country
CHAPTER 7: INTRANASAL DRUG DELIVERY DEVICES MARKET, BY REGION
7.1. Market Overview
7.1.1 Market Size and Forecast, By Region
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, By System
7.2.3. Market Size and Forecast, By Container
7.2.4. Market Size and Forecast, By Application
7.2.5. Market Size and Forecast, By Country
7.2.6. U.S. Intranasal Drug Delivery Devices Market
7.2.6.1. Market Size and Forecast, By System
7.2.6.2. Market Size and Forecast, By Container
7.2.6.3. Market Size and Forecast, By Application
7.2.7. Canada Intranasal Drug Delivery Devices Market
7.2.7.1. Market Size and Forecast, By System
7.2.7.2. Market Size and Forecast, By Container
7.2.7.3. Market Size and Forecast, By Application
7.2.8. Mexico Intranasal Drug Delivery Devices Market
7.2.8.1. Market Size and Forecast, By System
7.2.8.2. Market Size and Forecast, By Container
7.2.8.3. Market Size and Forecast, By Application
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, By System
7.3.3. Market Size and Forecast, By Container
7.3.4. Market Size and Forecast, By Application
7.3.5. Market Size and Forecast, By Country
7.3.6. France Intranasal Drug Delivery Devices Market
7.3.6.1. Market Size and Forecast, By System
7.3.6.2. Market Size and Forecast, By Container
7.3.6.3. Market Size and Forecast, By Application
7.3.7. Germany Intranasal Drug Delivery Devices Market
7.3.7.1. Market Size and Forecast, By System
7.3.7.2. Market Size and Forecast, By Container
7.3.7.3. Market Size and Forecast, By Application
7.3.8. Italy Intranasal Drug Delivery Devices Market
7.3.8.1. Market Size and Forecast, By System
7.3.8.2. Market Size and Forecast, By Container
7.3.8.3. Market Size and Forecast, By Application
7.3.9. Spain Intranasal Drug Delivery Devices Market
7.3.9.1. Market Size and Forecast, By System
7.3.9.2. Market Size and Forecast, By Container
7.3.9.3. Market Size and Forecast, By Application
7.3.10. UK Intranasal Drug Delivery Devices Market
7.3.10.1. Market Size and Forecast, By System
7.3.10.2. Market Size and Forecast, By Container
7.3.10.3. Market Size and Forecast, By Application
7.3.11. Rest Of Europe Intranasal Drug Delivery Devices Market
7.3.11.1. Market Size and Forecast, By System
7.3.11.2. Market Size and Forecast, By Container
7.3.11.3. Market Size and Forecast, By Application
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, By System
7.4.3. Market Size and Forecast, By Container
7.4.4. Market Size and Forecast, By Application
7.4.5. Market Size and Forecast, By Country
7.4.6. China Intranasal Drug Delivery Devices Market
7.4.6.1. Market Size and Forecast, By System
7.4.6.2. Market Size and Forecast, By Container
7.4.6.3. Market Size and Forecast, By Application
7.4.7. Japan Intranasal Drug Delivery Devices Market
7.4.7.1. Market Size and Forecast, By System
7.4.7.2. Market Size and Forecast, By Container
7.4.7.3. Market Size and Forecast, By Application
7.4.8. India Intranasal Drug Delivery Devices Market
7.4.8.1. Market Size and Forecast, By System
7.4.8.2. Market Size and Forecast, By Container
7.4.8.3. Market Size and Forecast, By Application
7.4.9. South Korea Intranasal Drug Delivery Devices Market
7.4.9.1. Market Size and Forecast, By System
7.4.9.2. Market Size and Forecast, By Container
7.4.9.3. Market Size and Forecast, By Application
7.4.10. Australia Intranasal Drug Delivery Devices Market
7.4.10.1. Market Size and Forecast, By System
7.4.10.2. Market Size and Forecast, By Container
7.4.10.3. Market Size and Forecast, By Application
7.4.11. Rest of Asia-Pacific Intranasal Drug Delivery Devices Market
7.4.11.1. Market Size and Forecast, By System
7.4.11.2. Market Size and Forecast, By Container
7.4.11.3. Market Size and Forecast, By Application
7.5. LAMEA
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, By System
7.5.3. Market Size and Forecast, By Container
7.5.4. Market Size and Forecast, By Application
7.5.5. Market Size and Forecast, By Country
7.5.6. Brazil Intranasal Drug Delivery Devices Market
7.5.6.1. Market Size and Forecast, By System
7.5.6.2. Market Size and Forecast, By Container
7.5.6.3. Market Size and Forecast, By Application
7.5.7. South Africa Intranasal Drug Delivery Devices Market
7.5.7.1. Market Size and Forecast, By System
7.5.7.2. Market Size and Forecast, By Container
7.5.7.3. Market Size and Forecast, By Application
7.5.8. Saudi Arabia Intranasal Drug Delivery Devices Market
7.5.8.1. Market Size and Forecast, By System
7.5.8.2. Market Size and Forecast, By Container
7.5.8.3. Market Size and Forecast, By Application
7.5.9. Rest of LAMEA Intranasal Drug Delivery Devices Market
7.5.9.1. Market Size and Forecast, By System
7.5.9.2. Market Size and Forecast, By Container
7.5.9.3. Market Size and Forecast, By Application
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping Of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. AptarGroup, Inc.
9.1.1. Company Overview
9.1.2. Key Executives
9.1.3. Company Snapshot
9.1.4. Operating Business Segments
9.1.5. Product Portfolio
9.1.6. Business Performance
9.1.7. Key Strategic Moves and Developments
9.2. Teleflex Incorporated
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Operating Business Segments
9.2.5. Product Portfolio
9.2.6. Business Performance
9.2.7. Key Strategic Moves and Developments
9.3. Nemera
9.3.1. Company Overview
9.3.2. Key Executives
9.3.3. Company Snapshot
9.3.4. Operating Business Segments
9.3.5. Product Portfolio
9.3.6. Business Performance
9.3.7. Key Strategic Moves and Developments
9.4. Becton, Dickinson And Company
9.4.1. Company Overview
9.4.2. Key Executives
9.4.3. Company Snapshot
9.4.4. Operating Business Segments
9.4.5. Product Portfolio
9.4.6. Business Performance
9.4.7. Key Strategic Moves and Developments
9.5. OptiNose, Inc.
9.5.1. Company Overview
9.5.2. Key Executives
9.5.3. Company Snapshot
9.5.4. Operating Business Segments
9.5.5. Product Portfolio
9.5.6. Business Performance
9.5.7. Key Strategic Moves and Developments
9.6. GlaxoSmithKline Plc.
9.6.1. Company Overview
9.6.2. Key Executives
9.6.3. Company Snapshot
9.6.4. Operating Business Segments
9.6.5. Product Portfolio
9.6.6. Business Performance
9.6.7. Key Strategic Moves and Developments
9.7. AstraZeneca
9.7.1. Company Overview
9.7.2. Key Executives
9.7.3. Company Snapshot
9.7.4. Operating Business Segments
9.7.5. Product Portfolio
9.7.6. Business Performance
9.7.7. Key Strategic Moves and Developments
9.8. Kurve Technology, Inc.
9.8.1. Company Overview
9.8.2. Key Executives
9.8.3. Company Snapshot
9.8.4. Operating Business Segments
9.8.5. Product Portfolio
9.8.6. Business Performance
9.8.7. Key Strategic Moves and Developments
9.9. Johnson And Johnson
9.9.1. Company Overview
9.9.2. Key Executives
9.9.3. Company Snapshot
9.9.4. Operating Business Segments
9.9.5. Product Portfolio
9.9.6. Business Performance
9.9.7. Key Strategic Moves and Developments
9.10. Merck And Co., Inc.
9.10.1. Company Overview
9.10.2. Key Executives
9.10.3. Company Snapshot
9.10.4. Operating Business Segments
9.10.5. Product Portfolio
9.10.6. Business Performance
9.10.7. Key Strategic Moves and Developments